OSIP: I don’t think today’s CHMP ruling on NSCLC maintenance therapy warrants any material “pot sweetening” by Astellas. CHMP rulings tend to be leaky, and hence Astellas has probably known the likely outcome of this application for a while. Moreover, reimbursement by the individual EU countries for the new maintenance indication could be problematic, IMO.
Market Data 
Markets 
AI
